Inicio・Lista de Acciones・ACADIA Pharmaceuticals Inc

ACADIA Pharmaceuticals Inc

Cerrado

SectorSanidad

29.61 0.78

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

28.97

Máximo

29.62

Métricas clave
By Trading Economics
Ingresos	-270M 3.6M
Ventas	-16M 268M
P/B Media del Sector	11.588 68.51
BPA	0.02
Margen de beneficios	1.357
Empleados	796
EBITDA	-19M 7M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	+16.64% upside

Dividendos
By Acuity
Próximas Ganancias	4 nov 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	586M 4.4B
Apertura anterior	28.83
Cierre anterior	29.61

Noticias sobre sentimiento de mercado

By Acuity

91%

9 / 340 Clasificación en Healthcare

ACADIA Pharmaceuticals Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

7 ago 2026, 20:06 UTC

ACADIA Pharmaceuticals Inc shares are advancing, maintaining a strong position above the 20-day moving average and near the upper end of their one-month range.

6 ago 2026, 23:41 UTC

ACADIA Pharmaceuticals shares are higher in after-market trading, reflecting strong performance above its 20-day moving average and nearing the upper end of its one-month range.

5 ago 2026, 20:02 UTC

News

ACADIA Pharmaceuticals shares rise following strong Q2 results and positive analyst ratings, with revenue guidance increased to $1.24 billion to $1.30 billion.

4 ago 2026, 23:01 UTC

News

Acadia Pharmaceuticals shares are higher after reporting strong Q2 results, with GAAP net sales of DAYBUE reaching $125 million and raising full-year revenue guidance.

3 ago 2026, 21:01 UTC

ACADIA Pharmaceuticals Inc shares are lower in after-market trading, continuing a trend of three consecutive sessions finishing lower without any specific news identified.

31 jul 2026, 20:03 UTC

ACADIA Pharmaceuticals shares are lower today, continuing a decline since Thursday's close. Rising Treasury yields and crude oil prices contribute to inflation concerns.

30 jul 2026, 19:58 UTC

ACADIA Pharmaceuticals shares are higher, reflecting a broader recovery in tech stocks amid improving market sentiment and bargain hunting after recent sell-offs.

29 jul 2026, 20:41 UTC

ACADIA Pharmaceuticals shares are lower in after-market trading amid a broader market decline linked to rising crude oil prices and geopolitical tensions.

28 jul 2026, 20:06 UTC

ACADIA Pharmaceuticals is rising amid strong performance in the Biotechnology sector. The stock is nearing the upper end of its one-month range.

27 jul 2026, 20:01 UTC

ACADIA Pharmaceuticals Inc. shares are higher today, continuing an upward trend since Friday's close, despite no specific news driving the price movement.

24 jul 2026, 19:56 UTC

ACADIA Pharmaceuticals shares are higher since Thursday's close, despite a dip earlier in the session. The stock remains below its 20-day moving average.

23 jul 2026, 10:06 UTC

ACADIA Pharmaceuticals is trading higher in pre-market hours, recovering from an earlier dip. The stock remains below its 20-day moving average.

22 jul 2026, 22:16 UTC

ACADIA Pharmaceuticals shares are lower in after-market trading, with unusual activity noted. Broader market concerns may be influencing investor sentiment.

21 jul 2026, 23:16 UTC

ACADIA Pharmaceuticals Inc. shares traded roughly flat in after-market hours, remaining near the upper end of their one-month trading range.

20 jul 2026, 19:56 UTC

Event

News

Social Media

Acadia Pharmaceuticals received Fast Track designation for remlifanserin, but shares are lower today, continuing a trend of declines over the past three sessions.

Comparación entre iguales

Cambio de precio

ACADIA Pharmaceuticals Inc previsión

Precio Objetivo

By TipRanks

16.64% repunte

Estimación a 12 Meses

Media 34.07 USD 16.64%

Máximo 39 USD

Mínimo 25 USD

De acuerdo con 15 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para ACADIA Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

15 ratings

Comprar

Mantener

Vender

De acuerdo con 15 analistas que ofrecen calificaciones bursátiles a para ACADIA Pharmaceuticals Inc Dist en los últimos 3 meses.

Sentimiento

By Acuity

9 / 340 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de ACADIA Pharmaceuticals Inc

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.